Compare MED & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MED | TVGN |
|---|---|---|
| Founded | 1980 | 2020 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Packaged Foods | Blank Checks |
| Sector | Consumer Staples | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.8M | 21.3M |
| IPO Year | 1996 | N/A |
| Metric | MED | TVGN |
|---|---|---|
| Price | $12.77 | $6.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 207.7K | 12.4K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $934,842,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.22 | $0.14 |
| 52 Week High | $14.67 | $12.03 |
| Indicator | MED | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.11 | 53.24 |
| Support Level | $9.90 | $6.33 |
| Resistance Level | $12.21 | $7.42 |
| Average True Range (ATR) | 0.56 | 0.67 |
| MACD | 0.33 | 0.35 |
| Stochastic Oscillator | 67.24 | 75.16 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.